First Trust Capital Management initiated a new position in Tri Pointe Homes (NYSE:TPH) during the first quarter, acquiring 1,599,172 shares in a trade estimated at $65.06 million based on quarterly average pricing, according to its May 14, 2026 SEC filing. According to a recent SEC filing , First Trust Capital Management established a new stake in Tri Pointe Homes by acquiring 1,599,172 shares in ...
First Trust Capital Management initiated a new position in Tri Pointe Homes (NYSE:TPH) during the first quarter, acquiring 1,599,172 shares in a trade estimated at $65.06 million based on quarterly average pricing, according to its May 14, 2026 SEC filing. According to a recent SEC filing , First Trust Capital Management established a new stake in Tri Pointe Homes by acquiring 1,599,172 shares in the first quarter of 2026. The transaction’s estimated value is $65.06 million, calculated using the mean unadjusted closing price during the quarter. The quarter-end value of the position was $74.73 million, reflecting both new share purchases and share price appreciation. Tri Pointe Homes, Inc. is a leading U.S. residential homebuilder with a multi-brand strategy and a presence in key growth markets. The company leverages operational scale and local market expertise to deliver a diversified product offering. Its integrated financial services enhance the homebuying experience and support customer retention. Continue reading
She brought the night to an end by reflecting on the expanse of her career, ending with the title track of her new Scandi-pop album Midnight Sun, before taking it all the way back to her 2017 collaboration with Clean Bandit on Symphony.
She brought the night to an end by reflecting on the expanse of her career, ending with the title track of her new Scandi-pop album Midnight Sun, before taking it all the way back to her 2017 collaboration with Clean Bandit on Symphony.
Key Points Superstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices. The quarter-end position value rose $6.55 million, reflecting the new stake. The trade represented a 4.16% increase in 13F reportable AUM. 10 stocks we like better than Vir Biotechnology › Superstring Capital Management disclosed a ...
Key Points Superstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices. The quarter-end position value rose $6.55 million, reflecting the new stake. The trade represented a 4.16% increase in 13F reportable AUM. 10 stocks we like better than Vir Biotechnology › Superstring Capital Management disclosed a new position in Vir Biotechnology (NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened According to a filing with the U.S. Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 shares purchased. The estimated transaction value was $5.82 million, based on the mean unadjusted closing price for the first quarter of 2026. The fund’s quarter-end position in Vir Biotechnology was valued at $6.55 million, reflecting both trading activity and price appreciation. What else to know Top holdings following the filing: NASDAQ: SMMT: $16.93 million (12.1% of AUM) NASDAQ: IMVT: $8.88 million (6.3% of AUM) NASDAQ: COGT: $8.67 million (6.2% of AUM) NASDAQ: SVRA: $8.66 million (6.2% of AUM) NASDAQ: URGN: $6.96 million (5.0% of AUM) As of Friday, Vir Biotechnology shares were priced at $9.19, up 99% over the past year and well outperforming the S&P 500, which is instead up about 28% in the same period. Company Overview Metric Value Revenue (TTM) $64.7 million Net Income (TTM) ($442.7 million) Price (as of Friday) $9.19 One-Year Price Change 99% Company Snapshot Vir develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV. The firm generates revenue primarily through product sales, licensing agreements, and strategic collaborations with pharmaceutical and biotechnology partners. It serves healthcare providers, government a...
The firm also cautioned that it is too early to assess the near-term competitive impact of Android XR-powered glasses because pricing, specifications and features have not yet been disclosed. Meta and eyewear giant EssilorLuxottica are also expected to ramp up marketing efforts ahead of anticipated launches from Alphabet and Apple Inc. . Counterpoint expects Google's partnership strategy to speed ...
The firm also cautioned that it is too early to assess the near-term competitive impact of Android XR-powered glasses because pricing, specifications and features have not yet been disclosed. Meta and eyewear giant EssilorLuxottica are also expected to ramp up marketing efforts ahead of anticipated launches from Alphabet and Apple Inc. . Counterpoint expects Google's partnership strategy to speed adoption across regions, especially in Asia-Pacific markets where Meta's availability remains limited. Still, the research firm said Google is unlikely to generate significant short-term profits from the category because hardware revenue will be shared with partners. Counterpoint said Google may also offer tighter integration with Android smartphones, improving contextual AI experiences such as reminders, cross-device syncing and calendar management. The report added that support for both Android and iOS devices could help Android XR-powered glasses attract Apple users in markets where iPhones remain dominant. According to Counterpoint Research , Meta currently controls roughly 80% of the global AI glasses market through its Ray-Ban Meta lineup. However, analysts believe Google's extensive portfolio of services — including Gmail, Google Maps, YouTube, Calendar, Photos and Google Meet — could significantly expand AI glasses use cases beyond photography and audio features. Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast Samsung is leading hardware design for the glasses, while Gentle Monster and Warby Parker are handling eyewear styling and optical support. Google is supplying the Android XR operating system, along with integration of its Gemini AI assistant and broader internet services ecosystem. The launch also deepens Google's partnerships with Samsung Electronics Co. Ltd. , South Korean eyewear brand Gentle Monster Co. Ltd. and Warby Parker Inc. as the company looks to accelerate commercialization and expand globally. Alphabet Inc. subsidia...
First Trust Capital Management established a new position in National Storage Affiliates Trust (NSA 0.16%) during the first quarter, buying an estimated $61.29 million in shares based on average quarterly pricing, according to a May 14, 2026, SEC filing. What happened According to an SEC filing dated May 14, 2026, First Trust Capital Management L.P. reported a new position in National Storage Affi...
First Trust Capital Management established a new position in National Storage Affiliates Trust (NSA 0.16%) during the first quarter, buying an estimated $61.29 million in shares based on average quarterly pricing, according to a May 14, 2026, SEC filing. What happened According to an SEC filing dated May 14, 2026, First Trust Capital Management L.P. reported a new position in National Storage Affiliates Trust, acquiring 1,814,200 shares. The estimated transaction value was $61.29 million, calculated using the average closing price for the quarter ending March 31, 2026. The stake’s quarter-end value was $68.47 million, a figure that incorporates both trading activity and changes in the stock’s price. What else to know This was a new position for the fund, representing 3.6% of its 13F assets under management after the trade. Top holdings post-filing: NYSE:GTLS: $130.63 million (6.9% of AUM) NASDAQ:HOLX: $100.38 million (5.3% of AUM) NYSE:SEE: $98.23 million (5.2% of AUM) NASDAQ:MASI: $85.27 million (4.5% of AUM) NASDAQ:EA: $82.77 million (4.3% of AUM) As of Friday, NSA shares were priced at $42.71, up about 26% over the past year, which is roughly in line with the S&P 500’s roughly 28% gain in the same period. Company overview Metric Value Revenue (TTM) $749.98 million Net Income (TTM) $78.57 million Dividend Yield 5% Price (as of Friday) $42.71 Company snapshot NSA operates and acquires self-storage properties across major U.S. metropolitan areas, generating revenue from rental income and related services. The firm employs a real estate investment trust (REIT) model, aggregating and managing a diversified portfolio of storage assets to drive recurring cash flow and scale efficiencies. It serves individuals, small businesses, and commercial clients seeking secure, flexible storage solutions in key growth markets. National Storage Affiliates Trust is a leading self storage REIT with a substantial footprint in the United States, focusing on ownership and operation of pr...
If you've got $1,000 burning a hole in your pocket that you're itching to invest, I've got three stocks that look like strong buys right now. All are set to be long-term beneficiaries of the artificial intelligence (AI) build-out, and buying them now secures your involvement in that future. The three stocks I think are solid AI picks right now are Amazon (AMZN 0.70%), Meta Platforms (META +0.52%),...
If you've got $1,000 burning a hole in your pocket that you're itching to invest, I've got three stocks that look like strong buys right now. All are set to be long-term beneficiaries of the artificial intelligence (AI) build-out, and buying them now secures your involvement in that future. The three stocks I think are solid AI picks right now are Amazon (AMZN 0.70%), Meta Platforms (META +0.52%), and Nebius (NBIS 2.34%). All of these companies are experiencing strong growth, and that could ramp up as AI becomes more prevalent. Amazon Amazon's involvement in the AI build-out stems from its cloud computing unit, Amazon Web Services (AWS). AWS is seeing monster demand for its computing resources, which is driving it to spend a whopping $200 billion on capital expenditures to expand its data center footprint this year alone. This $200 billion investment isn't speculative; Amazon already has agreements with several companies to lease this increased capacity. Expand NASDAQ : AMZN Amazon Today's Change ( -0.70 %) $ -1.89 Current Price $ 266.57 Key Data Points Market Cap $2.9T Day's Range $ 266.36 - $ 269.77 52wk Range $ 196.00 - $ 278.56 Volume 1.2M Avg Vol 45.2M Gross Margin 50.60 % Another reason why Amazon's platform is growing in popularity is that it has developed a set of custom AI chips that provide processing power at a lower price than GPUs. This business unit is growing at a triple-digit percentage rate year-over-year and has nearly sold out capacity for its latest chip generation, Trainium3. Its next generation, Trainium4, is nearly sold out already, even though those chips won't be available for 18 months. This all adds up to a business unit that's thriving, and with it growing in Q1 at a 28% pace (its fastest rate in 15 quarters), it makes for a strong case to buy the stock. AWS accounts for over half of Amazon's operating profits, so as AWS goes, so goes Amazon. Meta Platforms Meta Platforms may be making some major investments in its own AI business, but on...
Key Points Amazon's cloud computing platform is delivering strong growth. Meta Platforms is using AI to improve its ad business. Nebius is delivering unreal growth. These 10 stocks could mint the next wave of millionaires › If you've got $1,000 burning a hole in your pocket that you're itching to invest, I've got three stocks that look like strong buys right now. All are set to be long-term benefi...
Key Points Amazon's cloud computing platform is delivering strong growth. Meta Platforms is using AI to improve its ad business. Nebius is delivering unreal growth. These 10 stocks could mint the next wave of millionaires › If you've got $1,000 burning a hole in your pocket that you're itching to invest, I've got three stocks that look like strong buys right now. All are set to be long-term beneficiaries of the artificial intelligence (AI) build-out, and buying them now secures your involvement in that future. The three stocks I think are solid AI picks right now are Amazon (NASDAQ: AMZN), Meta Platforms (NASDAQ: META), and Nebius (NASDAQ: NBIS). All of these companies are experiencing strong growth, and that could ramp up as AI becomes more prevalent. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Amazon Amazon's involvement in the AI build-out stems from its cloud computing unit, Amazon Web Services (AWS). AWS is seeing monster demand for its computing resources, which is driving it to spend a whopping $200 billion on capital expenditures to expand its data center footprint this year alone. This $200 billion investment isn't speculative; Amazon already has agreements with several companies to lease this increased capacity. Another reason why Amazon's platform is growing in popularity is that it has developed a set of custom AI chips that provide processing power at a lower price than GPUs. This business unit is growing at a triple-digit percentage rate year-over-year and has nearly sold out capacity for its latest chip generation, Trainium3. Its next generation, Trainium4, is nearly sold out already, even though those chips won't be available for 18 months. This all adds up to a business unit that's thriving, and with it growing in Q1 at a 28% pace (its fastest rate in 15 quarters), it makes fo...
Key Points Pertento Partners acquired 815,333 shares of Astronics last quarter; the estimated trade size was $59.07 million based on quarterly average prices. The quarter-end value of the position changed by $54.41 million, reflecting both share purchases and price appreciation. The new stake places outside the fund’s top five holdings. 10 stocks we like better than Astronics › On May 14, 2026, Pe...
Key Points Pertento Partners acquired 815,333 shares of Astronics last quarter; the estimated trade size was $59.07 million based on quarterly average prices. The quarter-end value of the position changed by $54.41 million, reflecting both share purchases and price appreciation. The new stake places outside the fund’s top five holdings. 10 stocks we like better than Astronics › On May 14, 2026, Pertento Partners disclosed a new position in Astronics (NASDAQ:ATRO), acquiring 815,333 shares in the first quarter, an estimated $59.07 million trade based on quarterly average pricing. What happened According to a May 14, 2026, SEC filing, Pertento Partners LLP initiated a new position in Astronics by purchasing 815,333 shares. The estimated transaction value was $59.07 million, calculated using the quarterly average share price. The quarter-end value of the stake was $54.41 million, reflecting both the share count and stock price movements during the period. What else to know Top holdings post-filing: NYSE:USFD: $170.91 million (18.14% of AUM) NASDAQ:IESC: $110.18 million (11.69% of AUM) NYSE:PRMB: $99.80 million (10.59% of AUM) NASDAQ:CLBT: $91.81 million (9.74% of AUM) NASDAQ:PSMT: $78.96 million (8.38% of AUM) As of Friday, Astronics shares were priced at $80.86, up 170% over the past year and well outperforming the S&P 500, which is instead up about 28%. Company overview Metric Value Price (as of Friday) $80.86 Market capitalization $2.9 billion Revenue (TTM) $886.8 million Net income (TTM) $45.4 million Company snapshot Astronics designs and manufactures lighting and safety systems, electrical power generation and distribution systems, avionics, aircraft structures, and automated test systems for aerospace, defense, and electronics markets. The firm generates revenue primarily through product sales to OEMs, government contractors, and aircraft operators, with a diversified portfolio across aerospace and test systems segments. Its main customers include airframe manuf...
Key Points Pertento Partners reduced its SIMO holding by 738,875 shares; the estimated trade value was $89.68 million (based on quarterly average pricing). The quarter-end SIMO position value fell by $60.41 million, reflecting both share sales and price changes over the period. Post-trade, the fund held 412,536 SIMO shares valued at $46.32 million. 10 stocks we like better than Silicon Motion Tech...
Key Points Pertento Partners reduced its SIMO holding by 738,875 shares; the estimated trade value was $89.68 million (based on quarterly average pricing). The quarter-end SIMO position value fell by $60.41 million, reflecting both share sales and price changes over the period. Post-trade, the fund held 412,536 SIMO shares valued at $46.32 million. 10 stocks we like better than Silicon Motion Technology › Pertento Partners cut its stake in Silicon Motion Technology (NASDAQ:SIMO) in the first quarter, selling 738,875 shares in an estimated $89.68 million trade based on quarterly average pricing, according to a May 14, 2026, SEC filing. What happened Pertento Partners LLP disclosed in a May 14, 2026, SEC filing that it reduced its position in Silicon Motion Technology by 738,875 shares during the first quarter. The estimated value of shares sold was $89.68 million, calculated using the average closing price from January through March 2026. The fund’s quarter-end SIMO position was valued at $46.32 million, with total position value changing by $60.41 million over the period. What else to know Top holdings post-filing: NYSE:USFD: $170.91 million (18.1% of AUM) NASDAQ:IESC: $110.18 million (11.7% of AUM) NYSE:PRMB: $99.80 million (10.6% of AUM) NASDAQ:CLBT: $91.81 million (9.7% of AUM) NASDAQ:PSMT: $78.96 million (8.4% of AUM) As of Friday, SIMO shares were priced at $276.14, up about 325% over the past year and well outperforming the S&P 500, which is instead up about 28% in the same period. Company overview Metric Value Price (as of Friday) $276.14 Market Capitalization $9.4 billion Revenue (TTM) $1.06 billion Net Income (TTM) $169.97 million Company snapshot SIMO designs and markets NAND flash controllers for solid-state drives (SSDs), embedded storage, and specialized SSDs for industrial, commercial, and automotive applications. The firm generates revenue primarily by selling controller chips and storage solutions to device manufacturers, module makers, and hyperscal...
Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN) , selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing. According to a filing with the Securities and Exchange Commission dated May 14, 2026, Superstring Capital Management reduced its position in UroGen Pharma Ltd. ...
Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN) , selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing. According to a filing with the Securities and Exchange Commission dated May 14, 2026, Superstring Capital Management reduced its position in UroGen Pharma Ltd. by 330,983 shares. The estimated transaction value is $6.64 million, based on the average closing price for the quarter ended March 31, 2026. The quarter-end value of the position fell by $9.86 million, reflecting both share sales and price changes. UroGen Pharma Ltd. is a biotechnology company focused on advancing innovative therapies for urothelial cancers, leveraging proprietary RTGel technology and a robust clinical pipeline. The company pursues a strategy of addressing unmet medical needs in specialty oncology markets, with a particular emphasis on non-muscle invasive bladder cancer. Its competitive edge lies in its differentiated delivery platform and strategic collaborations with leading pharmaceutical and research institutions. Continue reading
Superstring Capital Management disclosed a new position in Vir Biotechnology (NASDAQ:VIR) , acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. According to a filing with the U.S. Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 sha...
Superstring Capital Management disclosed a new position in Vir Biotechnology (NASDAQ:VIR) , acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. According to a filing with the U.S. Securities and Exchange Commission dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 shares purchased. The estimated transaction value was $5.82 million, based on the mean unadjusted closing price for the first quarter of 2026. The fund’s quarter-end position in Vir Biotechnology was valued at $6.55 million, reflecting both trading activity and price appreciation. Vir Biotechnology, Inc. is a commercial-stage biotechnology company specializing in the development of innovative immunology-based therapies for serious infectious diseases. The company leverages collaborations with leading global partners to advance its pipeline and expand market reach. Vir's strategy centers on addressing unmet medical needs through scientific innovation and strategic alliances in the healthcare sector. Continue reading
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.32 to US$411.51 per share, reflecting incremental shifts in long term assumptions. Recent commentary links this change to how the first FDA accelerated approval f...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.32 to US$411.51 per share, reflecting incremental shifts in long term assumptions. Recent commentary links this change to how the first FDA accelerated approval for sonrotoclax and the evolving outlook for Brukinsa contribute to differing views on growth durability and execution risk. As you read on, you will see how these moving pieces shape the evolving narrative and what to watch to stay on top of it. Stay updated as the Fair Value for BeOne Medicines shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on BeOne Medicines. What Wall Street Has Been Saying 🐂 Bullish Takeaways Leerink raised its price target to US$367 after the FDA granted accelerated approval for sonrotoclax in relapsed or refractory mantle cell lymphoma, highlighting sonrotoclax as an emerging contributor alongside Brukinsa. Truist increased its price target to US$412 and pointed to the company outlook suggesting healthy Brukinsa growth even without major label expansion, which supports more confident long term revenue assumptions. RBC Capital lifted its price target to US$425 and noted that previously feared competition has left Brukinsa revenues largely unimpacted in recent periods, supporting the view that the core hematology franchise remains resilient. Barclays moved its target to US$405 and pointed to upcoming 2026 data disclosures as a potential source of longer term pipeline contribution beyond Brukinsa. 🐻 Bearish Takeaways Jefferies cut its price target to US$290 from US$420 and moved to a Hold rating, arguing that while Brukinsa is one of the stronger hematology assets, the stock does not appear mispriced at current levels and that the next growth drivers are slower to develop. Do your tho...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Advanced Micro Devices (NasdaqGS:AMD) is committing over $10b to expand advanced packaging capacity and AI partnerships across Taiwan. The company is aligning this investment with the production ramp of its 6th Gen EPYC "Venice" CPUs on TSMC's 2nm node. The in...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Advanced Micro Devices (NasdaqGS:AMD) is committing over $10b to expand advanced packaging capacity and AI partnerships across Taiwan. The company is aligning this investment with the production ramp of its 6th Gen EPYC "Venice" CPUs on TSMC's 2nm node. The initiative targets future AI infrastructure and data center demand by deepening AMD's ties with Taiwan's semiconductor supply chain. For investors watching NasdaqGS:AMD, this move lands after a strong share price run, with the stock at $467.51 and up 10.2% over the past week, 54.1% over the past month and 109.2% year to date. The stock is also up 323.8% over the past year and 483.8% over five years, which sets a backdrop of high expectations for any major capital commitment. This new Taiwan focused investment and the shift to TSMC's 2nm production place manufacturing scale and packaging technology at the center of AMD's AI and data center plans. For shareholders, the key questions now are how effectively this spend converts into reliable supply, product readiness for large AI workloads, and AMD's competitive position against other high end CPU and accelerator providers over the coming years. Stay updated on the most important news stories for Advanced Micro Devices by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Advanced Micro Devices. NasdaqGS:AMD Earnings & Revenue Growth as at May 2026 2 things going right for Advanced Micro Devices that this headline doesn't cover. AMD’s Taiwan investment plan ties directly into its push to make its 6th Gen EPYC “Venice” processor, built on TSMC’s 2nm process, the CPU backbone for next generation AI infrastructure. By committing over US$10b to advanced packaging and local partners such as ASE, SPIL and PTI, AMD is trying to secure the dense 2.5D and bridge interconnect pack...
On May 14, 2026, Pertento Partners disclosed a new position in Astronics (NASDAQ:ATRO) , acquiring 815,333 shares in the first quarter, an estimated $59.07 million trade based on quarterly average pricing. According to a May 14, 2026, SEC filing , Pertento Partners LLP initiated a new position in Astronics by purchasing 815,333 shares. The estimated transaction value was $59.07 million, calculated...
On May 14, 2026, Pertento Partners disclosed a new position in Astronics (NASDAQ:ATRO) , acquiring 815,333 shares in the first quarter, an estimated $59.07 million trade based on quarterly average pricing. According to a May 14, 2026, SEC filing , Pertento Partners LLP initiated a new position in Astronics by purchasing 815,333 shares. The estimated transaction value was $59.07 million, calculated using the quarterly average share price. The quarter-end value of the stake was $54.41 million, reflecting both the share count and stock price movements during the period. Astronics operates at scale within the aerospace and defense sector, serving a global customer base with a focus on advanced electronic systems and test solutions. The company leverages its engineering expertise to address the evolving needs of commercial, military, and general aviation markets. Its diversified product offering and established relationships with OEMs and government entities provide a strong competitive position in specialized, high-reliability applications. Continue reading
Key Points The Fairholme Fund sold 377,800 JOE shares for approximately $24.84 million across three days in May 2026. The sale reduced the Fund's position by 2.35%, leaving 15.7 million shares. Sale size was near the top of the Fund's historical range, but a large position remains. 10 stocks we like better than St. Joe › The Fairholme Fund, a concentrated mutual fund managed by Bruce Berkowitz, so...
Key Points The Fairholme Fund sold 377,800 JOE shares for approximately $24.84 million across three days in May 2026. The sale reduced the Fund's position by 2.35%, leaving 15.7 million shares. Sale size was near the top of the Fund's historical range, but a large position remains. 10 stocks we like better than St. Joe › The Fairholme Fund, a concentrated mutual fund managed by Bruce Berkowitz, sold 377,800 shares of The St. Joe Company (NYSE:JOE)across three open-market transactions between May 5 and May 7, 2026, for aggregate proceeds of approximately $24.84 million, according to a Form 4 filed with the SEC. Transaction summary Metric Value Shares sold (direct) 377,800 Transaction value $24.8 million Post-transaction shares (direct) 15,695,824 Post-transaction value (direct ownership) ~$1.02 billion Transaction value based on SEC Form 4 weighted average purchase price ($65.75); post-transaction value based on May 7, 2026 market close ($65.05). Key questions How does the transaction compare to Berkowitz's prior selling activity? This sale ranks in the upper decile by size among the Fairholme Fund's 35 JOE sell transactions since June 2023, with only one larger disposition (436,500 shares on May 7, 2024) and a mean historical sale size of ~145,400 shares. This sale ranks in the upper decile by size among the Fairholme Fund's 35 JOE sell transactions since June 2023, with only one larger disposition (436,500 shares on May 7, 2024) and a mean historical sale size of ~145,400 shares. Did the transaction meaningfully alter Berkowitz’s stake in The St. Joe Company? The sale reduced the fund’s direct position by 2.35%, modest relative to his remaining 15.7 million shares, which continue to represent a sizable ownership interest. The sale reduced the fund’s direct position by 2.35%, modest relative to his remaining 15.7 million shares, which continue to represent a sizable ownership interest. Was this activity related to options, derivatives, or indirect holdings? No deriv...
Key Points The Iran war led to a surge in energy stock prices. As tensions have cooled, share prices have stagnated. Earnings growth for the sector has been strong in 2026, but it's expected to turn negative in 2027. With downward pressures in earnings and likely lower oil prices once the Iran war comes to a resolution, energy stocks don't look like a buy right now. 10 stocks we like better than S...
Key Points The Iran war led to a surge in energy stock prices. As tensions have cooled, share prices have stagnated. Earnings growth for the sector has been strong in 2026, but it's expected to turn negative in 2027. With downward pressures in earnings and likely lower oil prices once the Iran war comes to a resolution, energy stocks don't look like a buy right now. 10 stocks we like better than Select Sector SPDR Trust - State Street Energy Select Sector SPDR ETF › Tech stocks are getting all the attention on Wall Street right now, but the best-performing sector year to date is still energy. The State Street Energy Select Sector SPDR ETF (NYSEMKT: XLE) is up 32% so far in 2026, which easily tops the S&P 500's (SNPINDEX: ^GSPC) 8.8% return and the 23% return of the State Street Technology Select Sector SPDR ETF (NYSEMKT: XLK). But all of those gains came during the first quarter of the year. So far in Q2, the XLE ETF is down about 2%, making it the second-worst-performing sector, behind only utilities. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The narrative right now is almost entirely around the Iran war. As tensions escalate and oil prices rise, energy stocks tend to rise as well and vice versa. That's an environment that can create a lot of volatility with little sustainable upside to show for it. As we head into summer with the timeline for an Iran war resolution still unknown, is the State Street Energy Select Sector SPDR ETF even worth considering? The case for investing in XLE is still largely geopolitical Oil prices have been whipsawing in 2026, ranging from about $90 a barrel for Brent crude to $120. The biggest catalyst for this, of course, is the discourse emerging from Washington regarding the conflict. It's difficult to say what the status of the war is at any given moment. We'v...
Mary Swift/iStock via Getty Images Overview When I previously covered the PIMCO Income Strategy Fund ( PFL ), I issued a buy rating due to its efficient portfolio strategy. Unfortunately, the share price has declined and its total return has suffered since then. Despite this, the underlying NAV has held up quite well. Therefore, I wanted to revisit PFL to reassess its most updated reporting and it...
Mary Swift/iStock via Getty Images Overview When I previously covered the PIMCO Income Strategy Fund ( PFL ), I issued a buy rating due to its efficient portfolio strategy. Unfortunately, the share price has declined and its total return has suffered since then. Despite this, the underlying NAV has held up quite well. Therefore, I wanted to revisit PFL to reassess its most updated reporting and its outlook for the remainder of the year. I think the fund can be valuable to income investors but there are some caveats that should be considered. For instance, the fund isn't structurally built to provide meaningful capital appreciation over time. As long as you understand that, there is value with PFL. Looking at the performance over the last twelve months, we can see that PFL's share price has declined by about 5.8%. However, all distributions paid offset this and brings the total return up to 5.6% over the same time frame. PFL now offers investors a starting dividend yield of 12.7%, while issuing those payouts on a monthly basis. The latest reporting indicates that the fund may have some trouble generating sufficient earnings to support the payouts. Despite this, I don't think the fund is at risk of a dividend cut. Although a reduction in payouts would improve long-term performance, I know the fund managers value a consistent payout. Data by YCharts The decline in share price has caused the fund to trade at a more favorable price to NAV valuation. While this could justify the accumulation of shares, the outlook of the fund is ultimately reliant on a healthier debt environment. A scenario where interest rates continue to decline can improve underlying earnings and NAV growth. Conversely, a scenario of higher interest rates will continue to suppress the fund's recovery. So let's start by taking a look at the underlying fund strategy. Fund Strategy According to the fund's latest overview , PFL now has total managed assets of $436M that are spread across a diverse range of...
Flywire (NASDAQ:FLYW) CEO Mike Massaro said the payments company is seeing benefits from a strategic review that focused on streamlining operations, improving data and systems, and reinvesting in priority areas. Speaking in a fireside chat with Tien-Tsin Huang, Payments and IT Services Analyst at JPMorgan, Massaro said Flywire responded to changes in some of its end markets with a “three-pronged a...
Flywire (NASDAQ:FLYW) CEO Mike Massaro said the payments company is seeing benefits from a strategic review that focused on streamlining operations, improving data and systems, and reinvesting in priority areas. Speaking in a fireside chat with Tien-Tsin Huang, Payments and IT Services Analyst at JPMorgan, Massaro said Flywire responded to changes in some of its end markets with a “three-pronged approach” that included organizational streamlining, optimization across geographies and products, and reinvestment in selected regions, products and teams. “We feel really good about the work we did, and I think we’re in a great position to scale,” Massaro said. Complex Payments Remain Core to Flywire’s Strategy Massaro said Flywire’s businesses in education, travel, healthcare and B2B payments are tied together by a focus on complex payment flows. He said the company targets clients with challenging billing processes, international payment needs or industry-specific systems of record. “We like to run in towards complexity as a team,” Massaro said, adding that Flywire uses industry-focused software along with a shared payments platform and infrastructure. He cited wins with educational institutions such as Cornell and Penn State, as well as Cleveland Clinic in healthcare, as examples of the types of complex payment problems Flywire aims to solve. Travel Business Focused on Hospitality Expansion Massaro said Flywire’s travel business has two main parts: a hospitality business that is currently “heavily U.S.-centric” and a luxury and experiential travel business. He said the two are about equal in size and both are growing well within Flywire. The hospitality business includes Sertifi, which Flywire acquired to expand into hotel back-office workflows such as documentation, signatures and payment processing for events including weddings, conferences and corporate gatherings. Massaro said the company is preparing for an international launch of the hospitality product from the e...
Pertento Partners cut its stake in Silicon Motion Technology (NASDAQ:SIMO) in the first quarter, selling 738,875 shares in an estimated $89.68 million trade based on quarterly average pricing, according to a May 14, 2026, SEC filing. Pertento Partners LLP disclosed in a May 14, 2026, SEC filing that it reduced its position in Silicon Motion Technology by 738,875 shares during the first quarter. Th...
Pertento Partners cut its stake in Silicon Motion Technology (NASDAQ:SIMO) in the first quarter, selling 738,875 shares in an estimated $89.68 million trade based on quarterly average pricing, according to a May 14, 2026, SEC filing. Pertento Partners LLP disclosed in a May 14, 2026, SEC filing that it reduced its position in Silicon Motion Technology by 738,875 shares during the first quarter. The estimated value of shares sold was $89.68 million, calculated using the average closing price from January through March 2026. The fund’s quarter-end SIMO position was valued at $46.32 million, with total position value changing by $60.41 million over the period. Silicon Motion Technology is a leading supplier of NAND flash controllers and storage solutions, operating at scale with a global customer base. The company leverages proprietary technology and a diversified product portfolio to address the needs of computing, enterprise, and industrial storage markets. Its established relationships with major OEMs and flash memory producers underpin a competitive edge in the fast-evolving semiconductor sector. Continue reading